| Name | Title | Contact Details |
|---|---|---|
Charles Marra |
Vice President of Technology | Profile |
Nick Gianadda |
Chief Technology Officer | Profile |
NOVOS develops science-based solutions to slow down human aging. NOVOS is a Public Benefit Corporation devoted to improving human longevity & health.
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.
Human Genome Sciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.